Morgan Stanley Applied Genetic Technologies Corp Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.89 $3,519 - $10,801	12,137 Added 30.74%	51,626 $14,000
Q2 2022 Oct 27, 2022	SELL	$0.62 - $1.1 $2,200 - $3,903	-3,549 Reduced 8.25%	39,489 $30,000
Q2 2022 Aug 15, 2022	SELL	$0.62 - $1.1 $2,200 - $3,903	-3,549 Reduced 8.25%	39,489 $30,000
Q1 2022 Oct 27, 2022	BUY	$1.07 - $2.71 $3,797 - $9,617	3,549 Added 8.99%	43,038 $46,000
Q1 2022 May 13, 2022	SELL	$1.07 - $2.71 $224,514 - $568,631	-209,827 Reduced 82.98%	43,038 $46,000
Q4 2021 Feb 14, 2022	SELL	$1.87 - $2.91 $80,497 - $125,266	-43,047 Reduced 14.55%	252,865 $480,000
Q3 2021 Nov 15, 2021	BUY	$3.01 - $4.12 $890,695 - $1.22 Million	295,912 New	295,912 $890,000

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.